课题基金 / 基金详情

项目摘要

项目成果

KURT R. BRUNDEN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):该R 01申请描述了阿尔茨海默病(AD)药物发现计划,该计划基于以下发现:AD脑内的脂质氧化产物激活确定的神经元受体,导致淀粉样蛋白β(Ab)肽产生和积累增加。更具体地说,氧化的花生四烯酸产物异前列烷2FaIII与神经元上的血栓烷A2(TP)受体结合,并导致Ab所来源的淀粉样前体蛋白(APP)的表达增加。因此,预期TP受体阻断剂可防止异前列烷介导的APP和Ab升高,并且这已通过显示该受体的拮抗剂显著降低AD的已建立的Tg 2576小鼠模型中的Ab水平和斑块沉积而得到证实。虽然这些结果提供了使用TP受体阻断剂治疗AD的新治疗策略的重要验证,但我们发现,该靶点的现有拮抗剂具有较差的血脑屏障穿透性,这限制了它们作为潜在AD治疗剂的有用性。因此,在本申请中,我们提出开发用于治疗AD的新的脑渗透性TP受体阻断剂,具体目的是:1)合成新的改进的TP受体拮抗剂,并在一组集中的体外效力和安全性测定中对其进行评价,然后进行小鼠药代动力学测试,以鉴定脑渗透性化合物; 2)在正常小鼠中进行目标1的2-5种最佳候选化合物的放大合成和随后的测试,以确定它们的毒理学特征和相对治疗指数;和3)在AD的Tg 2576转基因小鼠模型中评价具有最佳安全性特征和治疗指数的1-3个化合物。这些研究的成功完成将产生一种或多种来自一类新的AD治疗剂的新型候选药物,其将具有减少AD脑中的Ab肽和老年斑的潜力。 公共卫生相关性:R 01申请中提出的研究旨在开发一类用于治疗阿尔茨海默病(AD)的新药。如果成功,这些药物可能有能力减缓AD进展和/或改善患有这种疾病的人的认知能力。
英文摘要
DESCRIPTION (provided by applicant): This R01 application describes an Alzheimer's disease (AD) drug discovery program that is based on the discovery that a lipid oxidation product within the AD brain activates a defined neuronal receptor, with a resulting increase of amyloid beta (Ab) peptide production and accumulation. More specifically, the oxidized arachidonic acid product, isoprostane 2FaIII, binds to the thromboxane A2 (TP) receptor on neurons and causes an increase in expression of the amyloid precursor protein (APP) from which Ab is derived. Accordingly, a TP receptor blocker would be expected to prevent isoprostane-mediated elevation of APP and Ab, and this has been confirmed by showing that an antagonist to this receptor significantly reduces Ab levels and plaque deposition in the established Tg2576 mouse model of AD. Although these results provide important validation of a new therapeutic strategy of using TP receptor blockers for the treatment of AD, we have discovered that existing antagonists to this target have poor blood-brain barrier penetration that limits their usefulness as potential AD therapeutics. Accordingly, we propose in this application to develop novel, brain- penetrant TP receptor blockers for the treatment of AD, with the specific aims of: 1) synthesizing new, improved TP receptor antagonists and evaluating them in a focused set of in vitro potency and safety assays, followed by mouse pharmacokinetic testing, to identify brain-penetrant compounds; 2) conducting scale-up synthesis and subsequent testing of the 2-5 best candidate compounds from Aim 1 in normal mice to determine their toxicological profiles and relative therapeutic indices; and 3) evaluating the 1-3 compounds with the best safety profiles and therapeutic indices in the Tg2576 transgenic mouse model of AD. The successful completion of these studies will result in one or more novel drug candidates from a new class of AD therapeutics that will have the potential of decreasing Ab peptides and senile plaques in the AD brain. PUBLIC HEALTH RELEVANCE: The studies proposed within this R01 application are directed toward the development of a new class of drugs for the treatment of Alzheimer's disease (AD). If successful, such drugs might have the ability to slow AD progression and/or improve the cognitive performance of those with this disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies
  • 批准号:
    10364719
  • 项目类别:
  • 资助金额:
    $74.61万
  • 财政年份:
    2019
  • 负责人:
    KURT R. BRUNDEN
  • 依托单位:
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies
  • 批准号:
    10398425
  • 项目类别:
  • 资助金额:
    $15.99万
  • 财政年份:
    2019
  • 负责人:
    KURT R. BRUNDEN
  • 依托单位:
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies
  • 批准号:
    10553899
  • 项目类别:
  • 资助金额:
    $31.15万
  • 财政年份:
    2019
  • 负责人:
    KURT R. BRUNDEN
  • 依托单位:
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment
  • 批准号:
    8478876
  • 项目类别:
  • 资助金额:
    $47.86万
  • 财政年份:
    2013
  • 负责人:
    KURT R. BRUNDEN
  • 依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2010
  • 负责人:
    梁胜
  • 依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2010
  • 负责人:
    郭亚芬
  • 依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究